Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India

February 5, 2021 Auto Bot Biosimilars, India, Marketing Authorization, receives 0

Shots:

  • The company received DCGI’s MA for Teriparatide (biosimilar) for the treatment of Osteoporosis vs anti-resorptive therapies such as bisphosphates and SERMs
  • The approved product will be marketed through Alkem Laboratories as well as it explore other potential partnering opportunities
  • Teriparatide will be launched in a fully compliant pen device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

The post Enzene Receives Marketing Authorization for Teriparatide (biosimilar) in India first appeared on PharmaShots.